Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): A combined analysis of three phase 3 trials.
Author(s): Treat J, Scagliotti GV, Peng G, Monberg MJ, Obasaju CK, Socinski MA
Affiliation(s): Eli Lilly and Company or one of its subsidiaries, Indianapolis, IN, USA.
Publication date & source: 2011-11-22, Lung Cancer., [Epub ahead of print]
INTRODUCTION: In a first-line study of advanced NSCLC, pemetrexed-cisplatin was more effective among patients with adenocarcinoma and large-cell carcinoma compared with gemcitabine-cisplatin (median survival of 11.8 versus 10.4 months, P=.005), while survival with pemetrexed-cisplatin was shorter than with gemcitabine-cisplatin in patients with squamous cell carcinoma. The comparability of pemetrexed-cisplatin to other commonly used regimens within histology subgroups needs to be explored. METHODS: This retrospective analysis combined the patient-level data from three phase 3 randomized controlled trials that compared the efficacy of different third generation platinum- and non-platinum based doublets. Unadjusted median survival times and Cox covariate-adjusted treatment hazard ratio (HR) estimates were calculated. Overall results and subgroups by histological type were reported. RESULTS: This combined analysis consisted of 3467 patients. In the overall analysis, adjusted HRs favored pemetrexed (HR <1.0) to each of the other 5 regimens, though none of these HRs were statistically significant. Among patients with non-squamous histology, pemetrexed-cisplatin produced favorable HRs to each of the other regimens, achieving statistical significance when compared with vinorelbine-cisplatin (HR=0.67; 95% confidence intervals [CI]: 0.50, 0.91) and gemcitabine-cisplatin (HR=0.85; 95% CI: 0.75, 0.97). Among patients with squamous histology, 4 of the 5 comparison regimens produced favorable HRs (HR >1.0) when compared with pemetrexed-cisplatin, with only the comparison with gemcitabine-cisplatin achieving statistical significance (HR=1.23; 95% CI: 1.00, 1.51). CONCLUSION: In the absence of randomized clinical trial data comparing pemetrexed-cisplatin to commonly used doublets in advanced NSCLC other than gemcitabine-cisplatin, this combined analysis of multiple trials provides estimates for such comparisons. Copyright (c) 2011 Elsevier Ireland Ltd. All rights reserved.